Study guide
10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols
Certified Pulmonary Function Technologist CPFT
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview & NBRC Certification Requirements
1.1 NBRC PFT Exam Logistics, Format, and Scoring Criteria 1.2 Scope of Practice, Candidate Admission Pathways, and Credential Maintenance 1.3 Professional Standards, Ethics, and Patient Safety in Diagnostic Testing
2 Chapter 2: Spirometry Equipment & Sensors
2.1 Volume-Displacement Spirometers: Water-Seal, Rolling-Seal, Bellows 2.2 Flow-Sensing Pneumotachometers: Fleisch, Lilly, Vortex, Turbine, Pitot Tube, Ultrasonic 2.3 Calibration Standards & 3-Liter Syringe Quality Control Verification
3 Chapter 3: Body Plethysmography & Hardware
3.1 Body Plethysmograph Principles: Pressure, Volume, and Variable-Pressure-Constant-Volume Design 3.2 Plethysmograph Calibration, Pressure Transducers, and Shutter Mechanics 3.3 Quality Control, Isothermal Corrections, and Leak Detection in Plethysmography
4 Chapter 4: Gas Analyzers, Environmental Sensors, & Infection Control
4.1 Rapid and Multi-Gas Analyzers: Infrared, Zirconium, Mass Spec, Electrochemical, Thermal Conductivity 4.2 Environmental Sensors, Barometric Pressure, Temperature, and BTPS Correction Factors 4.3 Infection Control, Equipment Decontamination, Disposable Filters, and Spaulding Classification 4.4 Monitors: Pulse Oximeters, Blood Pressure Devices, and ECG Equipment 4.5 Gas Delivery Systems, Valves, Absorbers, and Aerosol / Inhaler Devices
5 Chapter 5: Spirometry Protocols & ATS/ERS Criteria
5.1 Forced Vital Capacity (FVC) and Slow Vital Capacity (SVC) Testing Protocols 5.2 ATS/ERS Spirometry Acceptability, Repeatability, and Usability Criteria 5.3 Peak Expiratory Flow Rate (PEFR), Maximum Voluntary Ventilation (MVV), and Flow-Volume Loops
6 Chapter 6: Lung Volume Determination Protocols
6.1 Open-Circuit Nitrogen Washout Method: Principles, Equipment, and Calculation 6.2 Closed-Circuit Helium Dilution Method: Principles, Equipment, and Calculation 6.3 Thoracic Gas Volume (TGV/FRCpleth) and Comparison of Lung Volume Methods
7 Chapter 7: Diffusing Capacity & Bronchial Challenge Testing
7.1 Single-Breath Carbon Monoxide Diffusing Capacity (DLCO) Testing Protocol 7.2 DLCO Calculations, Hemoglobin/COHb/Altitude Corrections, and VA 7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols 7.4 Inhaled Medication Delivery Technique and Patient Education
8 Chapter 8: Cardiopulmonary Exercise & ABG Testing
8.1 Cardiopulmonary Exercise Testing (CPET) Protocols, VO2max, and Anaerobic Threshold 8.2 Six-Minute Walk Test (6MWT) Protocol, Desaturation Monitoring, and O2 Titration 8.3 Arterial Blood Gas (ABG) Sampling, Allen Test, Analyzer Maintenance, and Quality Control 8.4 Pulse Oximetry and Oxygen Assessment: Principles, Limitations, and Titration Data 8.5 CO-Oximetry / Hemoximetry: Measurement, Dyshemoglobins, and Clinical Implications 8.6 Exercise Monitoring Data: Blood Pressure Response and ECG Rhythm Analysis
9 Chapter 9: Reference Values & PFT Calculations
9.1 Predicted Value Equations, Reference Populations, and GLI 2012 / ATS/ERS 2022 Standards 9.2 BTPS, STPD, and ATPS Conversion Formulas and Calculations 9.3 Gas Exchange Formulas, Alveolar Air Equation, and Mechanical Calculations
10 Chapter 10: Pattern Recognition & Clinical PFT Interpretation
10.1 Obstructive Ventilatory Defects: Asthma, COPD, Emphysema, Chronic Bronchitis, Bronchiectasis 10.2 Restrictive Ventilatory Defects: Parenchymal, Chest Wall, and Neuromuscular Disorders 10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols
11 Chapter 11: Artifact Recognition & Quality Assurance
11.1 Spirometry Artifacts: Hesitation, Coughing, Early Termination, Glottic Closure, Leak 11.2 Lung Volume and DLCO Artifacts: Panting Frequency, Shutter Leaks, Breath-Hold Failure 11.3 Quality Control Charts, Westgard Rules, and Laboratory Quality Assurance
12 Chapter 12: Documentation, Compliance, & Emergency Safety
12.1 PFT Reporting Standards, Tabular Formats, and Interpretation Graphics 12.2 CPT Billing Codes, ICD-10 Coding, HIPAA Privacy, and EHR Compliance 12.3 Emergency Preparedness, Contraindications, and Patient Safety Management in PFT Lab
13 Chapter 13: Specialized Procedures, Home Testing & Longitudinal Data
13.1 Respiratory Muscle Strength: MIP, MEP, SNIP, and Cough Peak Flow 13.2 Sputum Sample Collection: Spontaneous and Induced Specimens 13.3 Home Testing Instruction: Home Spirometry, Peak Flow Diaries, and Home Oximetry 13.4 Pediatric Pulmonary Function Testing and Upright Versus Supine Spirometry 13.5 Serial Pulmonary Function Testing, Clinical History, Demographics, and Laboratory Quality Management
10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols
Key Takeaways Explain This Topic AI
A mixed ventilatory defect is defined by the concurrent presence of both airflow obstruction (FEV1/FVC < LLN) and lung volume restriction (TLC < LLN).
An isolated diffusion defect is characterized by normal spirometry (FEV1/FVC >= LLN) and normal lung volumes (TLC >= LLN) accompanied by a reduced DLCO (< LLN or < 80% predicted).
Primary clinical causes of isolated diffusion defects include Pulmonary Arterial Hypertension (PAH), pulmonary embolism, early interstitial lung disease, and severe anemia.
Two bronchodilator-response criteria are in play: the classic rule of at least 12% AND at least 200 mL change in FEV1 or FVC, and the ATS/ERS 2022 rule of a change greater than 10% of the predicted value.
Evaluating bronchodilator responsiveness is essential for distinguishing asthma (typically highly reversible) from COPD (often fixed or partially reversible) and guiding bronchodilator therapy.
Last updated: August 2026
10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols
Complex pulmonary function interpretation requires synthesizing multiple test modalities to identify overlapping physiological abnormalities and evaluate therapeutic responsiveness. When airflow obstruction and lung volume restriction coexist, or when gas exchange is impaired independently of mechanical lung function, specialized diagnostic criteria must be applied.
This section covers the diagnostic definitions of mixed ventilatory defects , the differential diagnosis of isolated diffusion defects , standardized bronchodilator reversibility protocols , and presents a master step-by-step diagnostic decision tree for the NBRC CPFT examination.
Mixed Ventilatory Defects
A mixed ventilatory defect represents the concurrent coexistence of both an obstructive ventilatory defect and a restrictive ventilatory defect in the same patient.
Diagnostic Criteria
To definitively establish a mixed ventilatory defect, PFT results must satisfy BOTH of the following physiological thresholds:
Airflow Obstruction: The measured F E V 1 / F V C FEV_1/FVC FE V 1 / F V C ratio is below the Lower Limit of Normal ( F E V 1 / F V C < LLN FEV_1/FVC < \text{LLN} FE V 1 / F V C < LLN or < 0.70 < 0.70 < 0.70 ).
Lung Volume Restriction: Total Lung Capacity is below the Lower Limit of Normal ( T L C < LLN TLC < \text{LLN} T L C < LLN or < 80 % < 80\% < 80% predicted). Mixed Ventilatory Defect = ( F E V 1 / F V C < LLN ) AND ( T L C < LLN ) \text{Mixed Ventilatory Defect} = (FEV_1/FVC < \text{LLN}) \quad \mathbf{\text{AND}} \quad (TLC < \text{LLN}) Mixed Ventilatory Defect = ( FE V 1 / F V C < LLN ) AND ( T L C < LLN )
Physiological Mechanisms and Etiologies
Severe Airflow Obstruction with Secondary Fibrosis / Overlap: Severe COPD or emphysema occurring in a patient who subsequently develops Idiopathic Pulmonary Fibrosis (Combined Pulmonary Fibrosis and Emphysema - CPFE).
Asthma with Structural Thoracic Disease: Severe persistent asthma in a patient with coexisting kyphoscoliosis or severe morbid obesity.
Granulomatous Diseases: Advanced Sarcoidosis or pneumoconiosis, which cause both central airway narrowing (obstruction) and extensive parenchymal scarring (restriction).
Diagnostic Caution: In severe airflow obstruction, severe air trapping elevates Residual Volume ( R V RV R V ) so dramatically that Forced Vital Capacity ( F V C FVC F V C ) is reduced. This produces a low F V C FVC F V C with a low F E V 1 / F V C FEV_1/FVC FE V 1 / F V C ratio. If T L C TLC T L C is measured and found to be normal or elevated ( T L C ≥ LLN TLC \ge \text{LLN} T L C ≥ LLN ), the patient has a pure obstructive defect with air trapping , NOT a mixed defect. Only a confirmed T L C < LLN TLC < \text{LLN} T L C < LLN validates a true mixed defect.
Isolated Diffusion Defects
An isolated diffusion defect occurs when gas transfer across the alveolar-capillary membrane is pathologically impaired despite completely normal mechanical lung properties.
Diagnostic Criteria
Spirometry: Normal ( F E V 1 / F V C ≥ LLN FEV_1/FVC \ge \text{LLN} FE V 1 / F V C ≥ LLN and F V C ≥ LLN FVC \ge \text{LLN} F V C ≥ LLN ).
Lung Volumes: Normal ( T L C ≥ LLN TLC \ge \text{LLN} T L C ≥ LLN and R V ≥ LLN RV \ge \text{LLN} R V ≥ LLN ).
Diffusing Capacity: Reduced ( D L C O < LLN DLCO < \text{LLN} D L CO < LLN or < 80 % < 80\% < 80% predicted) . Isolated Diffusion Defect = ( F E V 1 / F V C ≥ LLN ) + ( T L C ≥ LLN ) + ( D L C O < LLN ) \text{Isolated Diffusion Defect} = (FEV_1/FVC \ge \text{LLN}) + (TLC \ge \text{LLN}) + (DLCO < \text{LLN}) Isolated Diffusion Defect = ( FE V 1 / F V C ≥ LLN ) + ( T L C ≥ LLN ) + ( D L CO < LLN )
Differential Diagnosis of Isolated Low D L C O DLCO D L CO
When faced with an isolated low D L C O DLCO D L CO , the technologist must consider four major clinical categories:
Pulmonary Vascular Diseases:
Pulmonary Arterial Hypertension (PAH): Primary vascular remodeling obliterates pulmonary capillaries without affecting bronchial airways or alveolar spaces.
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) / Recurrent PE: Multiple pulmonary emboli obstruct capillary blood flow ( V c V_c V c ), dropping D L C O DLCO D L CO .
Early Interstitial Lung Disease (ILD):
Subclinical fibrotic thickening of the alveolar-capillary membrane ( D m D_m D m ) decreases D L C O DLCO D L CO months or years before structural lung volumes ( T L C TLC T L C ) drop below normal limits.
Hematologic Alterations (Anemia):
Hemoglobin ( H b Hb H b ) is the primary sink for carbon monoxide during the D L C O DLCO D L CO test. A low blood hemoglobin concentration reduces measured D L C O DLCO D L CO .
Mandatory Rule: D L C O DLCO D L CO values must be mathematically adjusted for patient hemoglobin using standard ATS/ERS correction equations before diagnosing intrinsic vascular or membrane pathology.
Opportunistic Infections & Early Infiltrative Disease:
Pneumocystis jirovecii pneumonia (PJP) in immunocompromised patients frequently presents with an isolated reduction in D L C O DLCO D L CO as its earliest diagnostic PFT marker. Clinical Cause of Low D L C O Primary Physiological Mechanism D L C O / V A Ratio Pulmonary Arterial Hypertension Loss of pulmonary capillary bed volume ( V c ) Reduced ( < LLN ) Severe Anemia (Uncorrected) Reduced hemoglobin binding sites Normal when corrected for Hb Early Scleroderma / ILD Alveolar membrane thickening ( D m ) Reduced ( < LLN ) Emphysema (Obstructive) Alveolar wall destruction + capillary loss Reduced ( < LLN ) \begin{array}{lcc}
- \hline
- \text{Clinical Cause of Low } DLCO & \text{Primary Physiological Mechanism} & DLCO/V_A \text{ Ratio} \\
- \hline
\text{Pulmonary Arterial Hypertension} & \text{Loss of pulmonary capillary bed volume } (V_c) & \text{Reduced } (< \text{LLN}) \\
\text{Severe Anemia (Uncorrected)} & \text{Reduced hemoglobin binding sites} & \text{Normal when corrected for Hb} \\
\text{Early Scleroderma / ILD} & \text{Alveolar membrane thickening } (D_m) & \text{Reduced } (< \text{LLN}) \\
\text{Emphysema (Obstructive)} & \text{Alveolar wall destruction + capillary loss} & \text{Reduced } (< \text{LLN}) \\
\hline
\end{array} Clinical Cause of Low D L CO Pulmonary Arterial Hypertension Severe Anemia (Uncorrected) Early Scleroderma / ILD Emphysema (Obstructive) Primary Physiological Mechanism Loss of pulmonary capillary bed volume ( V c ) Reduced hemoglobin binding sites Alveolar membrane thickening ( D m ) Alveolar wall destruction + capillary loss D L CO / V A Ratio Reduced ( < LLN ) Normal when corrected for Hb Reduced ( < LLN ) Reduced ( < LLN )
Bronchodilator Reversibility Protocol and ATS/ERS Criteria
Evaluating post-bronchodilator responsiveness is an essential component of diagnostic spirometry, helping differentiate reversible airway disease (asthma) from fixed airflow obstruction (COPD).
Medication Withholding Times Prior to Testing
To establish a valid pre-bronchodilator baseline, bronchodilators are withheld per the ATS/ERS 2019 schedule: SABA 4–6 h , SAMA (ipratropium) 12 h , LABA (formoterol, salmeterol) 24 h , ultra-LABA (indacaterol, vilanterol, olodaterol) 36 h , and LAMA (tiotropium, umeclidinium, aclidinium, glycopyrronium) 36–48 h . If the clinical question is whether function improves beyond the current regimen, ATS/ERS permits the patient to continue usual therapy, with that decision documented on the report.
Administration Protocol
Perform baseline pre-bronchodilator spirometry meeting ATS/ERS repeatability criteria.
Administer 4 individual puffs of Albuterol ( 90 mcg/puff 90 \text{ mcg/puff} 90 mcg/puff USP or 100 mcg/puff 100 \text{ mcg/puff} 100 mcg/puff actuarial) via a metered-dose inhaler (MDI) with a valved holding chamber (spacer), waiting 30 seconds between inhalations.
Wait 10 to 15 minutes , then repeat forced spirometry.
Two Published Criteria for a Positive Response
1. The classic criterion (still in wide clinical and NBRC use): an increase in F E V 1 FEV_1 FE V 1 or F V C FVC F V C of ≥ 12 % \ge 12\% ≥ 12% AND ≥ 200 mL \ge 200\text{ mL} ≥ 200 mL relative to the pre-bronchodilator baseline. Both conditions must be satisfied by the same parameter — a 15% rise that equals only 150 mL is negative. Percent Change = Post-BD Value − Pre-BD Value Pre-BD Value × 100 \text{Percent Change} = \frac{\text{Post-BD Value} - \text{Pre-BD Value}}{\text{Pre-BD Value}} \times 100 Percent Change = Pre-BD Value Post-BD Value − Pre-BD Value × 100
2. The current criterion (ATS/ERS 2022 interpretive strategies): an increase in F E V 1 FEV_1 FE V 1 or F V C FVC F V C of more than 10% of the patient's predicted value . Response (2022) = Post-BD Value − Pre-BD Value Predicted Value × 100 > 10 % \text{Response (2022)} = \frac{\text{Post-BD Value} - \text{Pre-BD Value}}{\text{Predicted Value}} \times 100 > 10\% Response (2022) = Predicted Value Post-BD Value − Pre-BD Value × 100 > 10%
The 2022 task force moved to a percent- predicted denominator because expressing change as a percentage of a small baseline systematically over-calls reversibility in severe obstruction, where a tiny absolute gain is a large percentage of a tiny baseline, and under-calls it in patients whose baseline is near normal. Teach and recognize both frameworks: items written before 2022 use 12% + 200 mL, and clinical reports increasingly carry the percent-predicted form.
Worked comparison. Baseline F E V 1 FEV_1 FE V 1 1.60 L, predicted 3.20 L, post-BD 1.82 L. Absolute change 0.220 L. Classic criterion: 220 mL is ≥ 200 \ge 200 ≥ 200 mL and 13.75% is ≥ 12 % \ge 12\% ≥ 12% , so positive . 2022 criterion: 0.220 / 3.20 = 6.9% of predicted, which is not > 10 % > 10\% > 10% , so negative . Identical data, opposite conclusions — which is exactly why the report must state the criterion applied.
Master Step-by-Step PFT Interpretation Decision Tree
When analyzing complete PFT panel data on the CPFT exam, follow this standardized 5-step decision algorithm: Step 1: Inspect FEV1/FVC Ratio
- ├── Below LLN (< 0.70) ──► OBSTRUCTION PRESENT ──► Go to Step 2
- └── Normal/High (>= LLN) ─► NO OBSTRUCTION ──────► Go to Step 3
- Step 2: Inspect TLC (Airflow Obstruction Branch)
- ├── TLC < LLN ──────────► MIXED VENTILATORY DEFECT (Obstructive + Restrictive)
- └── TLC >= LLN ─────────► PURE OBSTRUCTIVE VENTILATORY DEFECT
- ├── Evaluate FEV1 % Predicted for Severity
- ├── Check DLCO (Low = Emphysema; Normal = Bronchitis/Asthma)
- └── Check BD Reversibility (+12% and +200 mL)
- Step 3: Inspect TLC (Non-Obstructive Branch)
- ├── TLC < LLN ──────────► PURE RESTRICTIVE VENTILATORY DEFECT
- │ ├── Check DLCO (Low = Parenchymal Fibrosis)
- │ └── Check DLCO & RV/TLC (Normal DLCO + High RV/TLC = Neuromuscular/Chest Wall)
- └── TLC >= LLN ─────────► LUNG VOLUMES NORMAL ───► Go to Step 4
- Step 4: Inspect DLCO (Spirometry & Volumes Normal)
- ├── DLCO < LLN ─────────► ISOLATED DIFFUSION DEFECT (Pulmonary Vascular, Early ILD, Anemia)
- └── DLCO >= LLN ────────► NORMAL PULMONARY FUNCTION TEST